Opgen Inc (OPGN)

$2.87

+0.33

(+12.9%)▲

Live

Insights on Opgen Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 913.44K → 699.02K (in $), with an average decrease of 12.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -14.69M → -4.06M (in $), with an average increase of 38.3% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 45.7% return, outperforming this stock by 109.4%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.6% return, outperforming this stock by 179.0%

Performance

  • $2.56
    $3.08
    $2.87
    downward going graph

    10.8%

    Downside

    Day's Volatility :16.88%

    Upside

    6.82%

    downward going graph
  • $1.65
    $38.40
    $2.87
    downward going graph

    42.51%

    Downside

    52 Weeks Volatility :95.7%

    Upside

    92.53%

    downward going graph

Returns

PeriodOpgen IncIndex (Russel 2000)
3 Months
-56.35%
0.0%
6 Months
-41.95%
0.0%
1 Year
-63.15%
0.0%
3 Years
-99.39%
-22.6%

Highlights

Market Capitalization
3.8M
Book Value
$2.67
Earnings Per Share (EPS)
-61.71
PEG Ratio
0.0
Wall Street Target Price
3.0
Profit Margin
0.0%
Operating Margin TTM
-510.09%
Return On Assets TTM
-44.91%
Return On Equity TTM
-314.92%
Revenue TTM
3.1M
Revenue Per Share TTM
5.48
Quarterly Revenue Growth YOY
55.800000000000004%
Gross Profit TTM
-9.0M
EBITDA
-16.9M
Diluted Eps TTM
-61.71
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-103.68
EPS Estimate Next Year
-0.29
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
-0.25

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Opgen Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 4.53%

Current $2.87
Target $3.00

Company Financials

FY18Y/Y Change
Revenue
2.9M
↓ 8.24%
Net Income
-12.6M
↓ 17.89%
Net Profit Margin
-428.99%
↑ 50.39%
FY19Y/Y Change
Revenue
3.5M
↑ 18.75%
Net Income
-11.7M
↓ 7.33%
Net Profit Margin
-334.78%
↑ 94.21%
FY20Y/Y Change
Revenue
4.2M
↑ 20.46%
Net Income
-26.2M
↑ 123.78%
Net Profit Margin
-621.93%
↓ 287.15%
FY21Y/Y Change
Revenue
4.3M
↑ 2.17%
Net Income
-34.8M
↑ 32.79%
Net Profit Margin
-808.3%
↓ 186.37%
FY22Y/Y Change
Revenue
2.6M
↓ 39.45%
Net Income
-36.7M
↑ 5.56%
Net Profit Margin
-1.4K%
↓ 600.92%
FY23Y/Y Change
Revenue
3.1M
↑ 17.76%
Net Income
-26.2M
↓ 28.8%
Net Profit Margin
-852.12%
↑ 557.1%
Q2 FY22Q/Q Change
Revenue
967.2K
↑ 105.9%
Net Income
-6.4M
↓ 17.43%
Net Profit Margin
-662.59%
↑ 989.73%
Q3 FY22Q/Q Change
Revenue
448.7K
↓ 53.61%
Net Income
-14.7M
↑ 129.3%
Net Profit Margin
-3.3K%
↓ 2612.26%
Q4 FY22Q/Q Change
Revenue
721.6K
↑ 60.82%
Net Income
-10.0M
↓ 32.13%
Net Profit Margin
-1.4K%
↑ 1892.83%
Q1 FY23Q/Q Change
Revenue
913.4K
↑ 26.58%
Net Income
-7.0M
↓ 29.61%
Net Profit Margin
-768.56%
↑ 613.46%
Q2 FY23Q/Q Change
Revenue
736.1K
↓ 19.41%
Net Income
-5.8M
↓ 16.99%
Net Profit Margin
-791.61%
↓ 23.05%
Q3 FY23Q/Q Change
Revenue
699.0K
↓ 5.04%
Net Income
-4.1M
↓ 30.28%
Net Profit Margin
-581.23%
↑ 210.38%
FY17Y/Y Change
Total Assets
6.6M
↓ 26.31%
Total Liabilities
5.2M
↓ 10.27%
FY18Y/Y Change
Total Assets
9.0M
↑ 35.2%
Total Liabilities
5.6M
↑ 8.1%
FY19Y/Y Change
Total Assets
10.4M
↑ 16.44%
Total Liabilities
6.1M
↑ 8.63%
FY20Y/Y Change
Total Assets
49.8M
↑ 377.37%
Total Liabilities
28.6M
↑ 366.02%
FY21Y/Y Change
Total Assets
71.7M
↑ 44.05%
Total Liabilities
30.4M
↑ 6.62%
FY22Y/Y Change
Total Assets
25.8M
↓ 63.96%
Total Liabilities
18.3M
↓ 40.05%
Q2 FY22Q/Q Change
Total Assets
48.8M
↓ 24.04%
Total Liabilities
21.4M
↓ 28.72%
Q3 FY22Q/Q Change
Total Assets
33.0M
↓ 32.47%
Total Liabilities
19.0M
↓ 11.31%
Q4 FY22Q/Q Change
Total Assets
25.8M
↓ 21.63%
Total Liabilities
18.3M
↓ 4.03%
Q1 FY23Q/Q Change
Total Assets
26.5M
↑ 2.64%
Total Liabilities
17.3M
↓ 5.04%
Q2 FY23Q/Q Change
Total Assets
22.4M
↓ 15.38%
Total Liabilities
15.6M
↓ 10.15%
Q3 FY23Q/Q Change
Total Assets
18.1M
↓ 19.17%
Total Liabilities
15.5M
↓ 0.75%
FY18Y/Y Change
Operating Cash Flow
-11.1M
↓ 22.58%
Investing Cash Flow
-137.3K
↓ 50.41%
Financing Cash Flow
13.8M
↑ 12.12%
FY19Y/Y Change
Operating Cash Flow
-11.5M
↑ 3.9%
Investing Cash Flow
-2.5M
↑ 1722.35%
Financing Cash Flow
12.2M
↓ 12.11%
FY20Y/Y Change
Operating Cash Flow
-23.4M
↑ 103.35%
Investing Cash Flow
-1.1M
↓ 57.5%
Financing Cash Flow
34.1M
↑ 180.13%
FY21Y/Y Change
Operating Cash Flow
-21.5M
↓ 8.19%
Investing Cash Flow
-2.0M
↑ 86.52%
Financing Cash Flow
47.5M
↑ 39.21%
Q2 FY22Q/Q Change
Operating Cash Flow
-6.7M
↑ 32.1%
Investing Cash Flow
-44.9K
↑ 15.85%
Financing Cash Flow
-6.8M
↑ 38863.87%
Q3 FY22Q/Q Change
Operating Cash Flow
-4.8M
↓ 28.61%
Investing Cash Flow
-103.0K
↑ 129.64%
Financing Cash Flow
-899.3K
↓ 86.83%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.0M
↓ 15.97%
Investing Cash Flow
-330.4K
↑ 220.84%
Financing Cash Flow
1.0M
↓ 212.43%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.0M
↑ 24.23%
Investing Cash Flow
-330.4K
↑ 0.0%
Financing Cash Flow
4.7M
↑ 369.14%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.8M
↓ 4.23%
Investing Cash Flow
-101.7K
↓ 69.21%
Financing Cash Flow
1.5M
↓ 68.29%
Q3 FY23Q/Q Change
Operating Cash Flow
-2.9M
↓ 38.39%
Investing Cash Flow
-101.7K
↑ 0.0%
Financing Cash Flow
27.5K
↓ 98.17%

Technicals Summary

Sell

Neutral

Buy

Opgen Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Opgen Inc
Opgen Inc
-47.15%
-41.95%
-63.15%
-99.39%
-99.86%
Stryker Corporation
Stryker Corporation
4.27%
16.65%
22.1%
34.77%
82.03%
Boston Scientific Corp.
Boston Scientific Corp.
4.07%
37.85%
46.89%
79.63%
93.34%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.26%
27.0%
2.23%
-8.36%
51.45%
Abbott Laboratories
Abbott Laboratories
-2.62%
-2.21%
-0.86%
-5.87%
32.8%
Medtronic Plc
Medtronic Plc
0.44%
2.96%
-1.92%
-33.69%
-13.02%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Opgen Inc
Opgen Inc
NA
NA
0.0
-103.68
-3.15
-0.45
NA
2.67
Stryker Corporation
Stryker Corporation
38.89
38.89
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.5
63.5
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.45
37.45
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.83
31.83
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.48
29.48
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Opgen Inc
Opgen Inc
Sell
$3.8M
-99.86%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$129.9B
82.03%
38.89
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
93.34%
63.5
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
51.45%
37.45
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$177.8B
32.8%
31.83
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-13.02%
29.48
11.36%

Institutional Holdings

  • Chase Investment Counsel Corp

    2.63%

  • Renaissance Technologies Corp

    0.52%

  • Vanguard Group Inc

    0.42%

  • Geode Capital Management, LLC

    0.29%

  • BlackRock Inc

    0.13%

  • Tower Research Capital LLC

    0.06%

Company Information

opgen, inc. (nasdaq: opgn) is harnessing the power of informatics and genomic analysis to provide complete solutions for infection prevention and treatment. using our large and ever-growing acuitas lighthouse® knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases. today, through our clia-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. our fda-cleared, ivd products rapidly identify pathogens in positive blood cultures.

Organization
Opgen Inc
Employees
85
CEO
Dr. Oliver Schacht Ph.D.
Industry
Health Technology

Discover More

FAQs